Overview

A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate subject perceptions of Olopatadine 0.2%, dosed once-daily, in subjects with allergic conjunctivitis and to record any adverse events as described by the subjects as a part of this post marketing surveillance study.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Olopatadine Hydrochloride
Ophthalmic Solutions
Pharmaceutical Solutions